Transcript
I would like also to highlight Abstract 9615, which is lorlatinib for advanced ALK-positive and ROS-positive NSCLC, efficacy from lorlato-expanded program.
This abstract gives us real-time data around lorlatinib efficacy.
As you know, lorlatinib is a third-generation ALK and ROS1 TKI. It's approved in the United States for patients who have failed at least one ALK TKI.
In this study, what the office did is that they provided us with real data from France. They showed that the response rate of lorlatinib in heavily pretreated ALK-positive patients (so, this cohort) 90% of the patients had first-generation ALK TKI and 88% had second-generation also. The response rate in this heavily pretreated population was 46% with a median PFS of 12 months. As for the ROS1 cohort, the response rate was 84% with a median PFS of 8 months.
These outcomes are similar to those reported in the Lancet Oncology paper of the phase 2 study.
It's great that we see that what's also positive in the phase 2 is consistent with real-world experience, as well.
We eagerly wait for the results of the phase 3 trial comparing lorlatinib with crizotinib in the first-line setting, and also the NRG-LU003, which will help us understand what the best sequence of ALK TKI is when we treat these patients.
